BioCentury
ARTICLE | Company News

MorphoSys licenses MOR103 to GSK

June 4, 2013 2:56 AM UTC

MorphoSys AG (Xetra:MOR; Pink:MPSYF) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exclusive, worldwide rights to develop and commercialize MOR103. MorphoSys will receive EUR 22.5 million ($29.3 mil...